Trump’s 25% Tariff Threat: K-Bio Gains ‘Tariff Freedom’ Through Plant Acquisitions
Trump Announces 25% Tariffs on Autos and Pharmaceuticals on January 26
Samsung Biologics and Celltrion Secure Local Production Bases in the U.S. Last Year
On January 26 (local time), U.S. President Donald Trump announced plans to impose a 25% reciprocal tariff on automobiles, pharmaceuticals, and other products, raising trade barriers. However, the domestic pharmaceutical and biotechnology industries are responding relatively calmly, forecasting only a 'limited impact.' Leading Korean biopharmaceutical companies such as Samsung Biologics and Celltrion have already pursued 'localization' strategies for years, acquiring production facilities or establishing sales bases in the United States. In addition, the price structure of domestically produced volumes is expected to help absorb the impact of Trump’s tariffs.
"Even the time to build a new plant is too precious"... Why the acquisition strategy was the right move
According to the industry on January 27, Samsung Biologics acquired a 60,000-liter drug substance (DS) plant in Rockville, Maryland, from GlaxoSmithKline (GSK) in December of last year. The acquisition price was $280 million (approximately 405.9 billion won). With additional investment after the acquisition, production capacity can be expanded to 100,000 liters. The acquisition is expected to be completed by the end of March this year. At this month’s JP Morgan Healthcare Conference main track, CEO John Rim stated, "This is the starting point for securing U.S. production capacity," adding, "In addition to our large-scale production platform centered in Korea (Songdo), we will also have production options in the U.S., supporting our customers’ supply chain diversification and resilience."
On the same day, Celltrion stated, "By securing a production facility in Branchburg, New Jersey, we have established a fundamental solution to the tariff issue and structurally eliminated all related risks. Product sales will continue without tariff impact, thanks to two years’ worth of supply already delivered to the U.S." In September of last year, Celltrion acquired the biopharmaceutical production facility of global pharmaceutical company Eli Lilly in Branchburg. Celltrion invested about $330 million (approximately 478.8 billion won) in this acquisition. At a press conference last year, Celltrion Group Chairman Seo Jungjin expressed strong confidence, saying, "We are now completely free from Trump-induced tariff risks through the acquisition of a U.S. plant."
Panoramic view of Samsung Biologics Plant 4 in Songdo, Incheon. Samsung Biologics
View original imageLotte Biologics also secured a U.S. production base in one stroke by acquiring Bristol Myers Squibb (BMS)’s Syracuse, New York plant for $160 million (approximately 231.9 billion won) in 2022. The 40,000-liter facility is equipped with an ADC (antibody-drug conjugate) production line, a next-generation modality that is gaining attention as a new therapeutic approach.
In response to tariff issues triggered by Trump, the strategy chosen by Korean biotech companies can be summarized as securing immediate response capabilities through the acquisition of existing plants. By shortening the three to four years required for a 'greenfield' build and enabling immediate local production in the U.S., these companies can be fundamentally excluded from tariff imposition.
Songdo products are 'drug substances,' not 'finished products'... Minimal tariff impact due to low unit price
It is widely analyzed that the 25% tariff will not be a fatal blow to shipments produced at the Songdo biocluster and exported to the U.S. The key lies in the price difference between drug substances (DS) and drug products (DP).
Aerial view of Celltrion Plant 2 in Songdo, Incheon. / Incheon ? Photo by Hyunmin Kim kimhyun81@
View original imageFor Korean CDMO (contract development and manufacturing organization) companies such as Samsung Biologics, the main export items produced in Songdo are drug substances, which are at a stage before final packaging, rather than finished drug products. The price of DS is only one-fifth to one-tenth that of DP, so even if a high tariff of 25% is actually imposed, the impact is minimal. For example, if the final sales price of a drug is 1 million won, importing the finished product would incur a tariff of 250,000 won, whereas importing at the substance stage (200,000 won) would result in a tariff of only 50,000 won. In most contracts, even this partial tariff is typically borne by the customer.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Korea Biotechnology Industry Organization stated in a briefing on this day, "Pharmaceuticals have been tariff-free since the Korea-U.S. Free Trade Agreement, and remain so today," adding, "Since the U.S. has not announced any plans to impose tariffs based on its investigation into the impact of pharmaceutical imports on national security, it is unlikely that a 25% tariff will be immediately applied to pharmaceuticals." Lee Seungkyu, Vice Chairman of the Korea Biotechnology Industry Organization, also commented, "While the intentions of the Trump administration are unclear, the impact on our biotech companies with established local bases will be extremely limited," indicating that the organization will continue to monitor developments.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.